Business
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practit
About this update from Biomerica, Inc.
[{"type":"image","alt":"Biomerica, Inc.","displaySize":"","headline":null,"caption":"Biomerica, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":232,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/af40ff522792b4c3d1be4034218ddeca"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m66J9gaNGHXIlBdKngBmxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/af40ff522792b4c3d1be4034218ddeca","width":232,"height":39}},"lazy":false},{"type":"text","content":"- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization Strategy","length":204,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, to market Biomerica’s inFoods® Irritable Bowel Syndrome (IBS) test in the United States, excluding New York State.","length":418,"tagName":"p"},{"type":"text","content":"Henry Schein’s powerful nationwide distribution network, comprised of more than 400 medical field sales and telesales representatives, will provide marketing support for the inFoods® IBS test to primary care and gastroenterology specialty practices. With more than 93 years in health care innovation and over $12 billion in annual sales in 2024, Henry Schein is well-positioned to accelerate adoption of this new, non-pharmaceutical precision-based diagnostic therapy for patients suffering from IBS.","length":500,"tagName":"p"},{"type":"text","content":"“We are thrilled to partner with Henry Schein to bring inFoods® IBS test to more patients and providers across the country,” said Zack Irani, CEO of Biomerica. “Their national reach and proven track record in delivering innovative medical products will help accelerate adoption of our non-drug, personalized solution for IBS management.”","length":337,"tagName":"p"},{"type":"text","content":"“Our team is dedicated to offering health care professionals the latest innovative solutions that ultimately enhance patient care, and we are pleased to collaborate wit...